Lasrado Ninaad, Barouch Dan H
Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
J Infect Dis. 2023 Nov 11;228(10):1311-1313. doi: 10.1093/infdis/jiad353.
Three and a half years into the coronavirus disease 2019 (COVID-19) pandemic, the nature and durability of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still remains unclear. Current COVID-19 mRNA vaccines have been shown to provide minimal protection against infection with XBB variants but substantial protection against severe disease. However, such protection appears to wane quickly. In contrast, protection from the combination of both vaccination and infection, termed "hybrid immunity", has been shown to be greater in magnitude and durability than that provided by either vaccine immunity or natural immunity alone.
在2019冠状病毒病(COVID-19)大流行三年半之后,针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的保护性质和持久性仍不清楚。目前的COVID-19信使核糖核酸疫苗已被证明对XBB变种感染提供的保护极小,但对重症有实质性保护。然而,这种保护似乎很快就会减弱。相比之下,接种疫苗和感染相结合所产生的保护作用,即“混合免疫”,已被证明在强度和持久性上都比单独的疫苗免疫或自然免疫提供的保护更大。